VISTA Regulates the Development of Protective Antitumor Immunity. - Wikidata - wikimedia - TriplyDB

VISTA Regulates the Development of Protective Antitumor Immunity.

VISTA Regulates the Development of Protective Antitumor Immunity.

http://www.wikidata.org/entity/Q33978040

about

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Melanoma: oncogenic drivers and the immune system Advances in immunotherapy for treatment of lung cancer Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators Immune escape mechanisms as a guide for cancer immunotherapy Targeting immune checkpoints in malignant glioma Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?Characterization of programmed death-1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals.Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53 Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens.Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.Selective Involvement of the Checkpoint Regulator VISTA in Suppression of B-Cell, but Not T-Cell, Responsiveness by Monocytic Myeloid-Derived Suppressor Cells from Mice Infected with an Immunodeficiency-Causing Retrovirus Inhibitory receptors as targets for cancer immunotherapy Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.A New VISTA on combination therapy for negative checkpoint regulator blockade.The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.Engineered Materials for Cancer Immunotherapy.Immunosuppressive cells in tumor immune escape and metastasis.Immune checkpoint inhibitors: a patent review (2010-2015).Leprosy as a model to understand cancer immunosurveillance and T cell anergy.Immunoregulatory functions of VISTA.Targeting PD-1/PD-L1 in lung cancer: current perspectives.Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.New B7 Family Checkpoints in Human Cancers.Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis.Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma.Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability.Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses.VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis.

P2860

Q26769884-ADB1E70B-BBE2-434E-9084-5D34F352404B Q26775598-A4A96AF9-5724-4D79-8E74-B34BD7DEC3BC Q26778790-55CFA5C8-6DAD-4B6F-9201-AAE343D34B87 Q26782799-AB48381B-270A-44D0-AD58-1A6273B8AACB Q27024502-4BB5A1C3-3E1B-4CF5-98FA-ED506FC0FFEA Q28072012-71D91079-088D-4575-AC69-7CB7D162A59E Q28072532-F77625F5-07C2-4A17-B8DE-48EA410933B0 Q33632116-5CCE2360-328D-4034-AC62-29B9D188B5BE Q34287251-A0F90E7B-578D-42F5-91A3-7CB84A61E402 Q34384017-7995F8AB-39F5-49E9-913B-BAB6714ACDBA Q34487653-EA934D28-AC2B-4A24-B60F-8FFF399215AA Q35613336-CE20735E-D229-405D-9A3C-A7137E58FCA2 Q35669414-E465AFC2-164A-489E-B3CC-CA4F991343FE Q35973689-3E6861A4-C551-4783-A433-3FEE5302871E Q35995373-F77315A8-CD89-414C-A72D-46706EC7EB18 Q36382143-4A4F8B76-DE35-447B-A86D-9B3B1934374F Q37158481-AA954ECA-DD05-495B-863A-A8E9DEC5BA02 Q37517581-B89A4179-EB3C-45F7-A64A-A392C055DA9D Q38304438-155600F5-5A7D-41E7-B725-38FAE10F6E6E Q38414485-78D09C8A-4157-467F-9E97-9BBFD2AB01D0 Q38636569-CFEF8242-0B18-42C9-8C0C-2789B57C72C8 Q38660577-8278DFFA-FFB5-4ED2-A6CF-D461766A073F Q38675140-09A142AC-9A8B-49D6-8453-CD3A4B25DE4F Q38800588-6DCF56B5-16B6-4717-A402-B8B3642A08D7 Q38815454-FCD83E1A-27B6-422B-99D4-EB7552272E5F Q38930123-B8B7490C-16AB-4FE8-8A0B-6D700B65FBBC Q38956294-764F799D-CFDF-4691-9119-CA179E1D68FF Q38996594-8C2B13B3-0C4B-42F1-A67F-8E0728E7AB1C Q39078341-23DF1B18-F18D-4057-9884-805ADE13D0EB Q39181190-13D1F9EC-EB33-4289-8C7A-0F24D3DFFDDB Q39189908-D789277C-8DA7-4B7B-957B-668FE62B4426 Q39313794-3B05D1B8-A5E9-459D-8E84-F111DC57EEFF Q39416195-6F0E2036-F74F-4CD4-9092-9AA19FABD4D3 Q40216414-6D6480C3-9EA7-4FB8-B125-6C7D64B0C8B0 Q40446457-DC851F68-8596-4A0C-B808-8CBC42E2BCE0 Q41075955-ED9FF36B-18B3-4787-AB76-9079AC5D36B7 Q41382123-C32D49D0-F777-45BE-9183-11AE0445EC80 Q41863599-ECCC3E26-9D2D-4424-8C6F-BBF3FD764A51 Q47139628-4ABE808C-7321-4E55-85BD-3050D4DB2F76 Q47151685-C4BADCD4-88A2-4DF9-8BE9-8F573EC8660D

P2860

VISTA Regulates the Development of Protective Antitumor Immunity.

http://www.wikidata.org/entity/Q33978040

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

VISTA Regulates the Development of Protective Antitumor Immunity.

@ast

VISTA Regulates the Development of Protective Antitumor Immunity.

@en

type

label

VISTA Regulates the Development of Protective Antitumor Immunity.

@ast

VISTA Regulates the Development of Protective Antitumor Immunity.

@en

prefLabel

VISTA Regulates the Development of Protective Antitumor Immunity.

@ast

VISTA Regulates the Development of Protective Antitumor Immunity.

@en

P1433

Q33978040-5A1B96B4-D005-48FD-9333-08B5E4ACC3EB

P1476

Q33978040-699F7F19-C700-4EB9-B112-7198925B1A07

P2093

Q33978040-1B6EABB0-23C1-4BB4-97AA-A19980C075A3

Q33978040-27455B5D-D567-4D89-9C6B-088C148C9EF5

Q33978040-33029ADF-F70E-444F-A78D-C9D615EAF969

Q33978040-8047AC5E-C1CA-475D-B9D4-CBFCFCD08673

Q33978040-90F0CAD9-EE48-48F3-9BC8-274CF258E0F8

Q33978040-AEB53666-D31F-498C-BCF6-F8BBBF0ACBF6

Q33978040-F2CC3382-2E34-4A00-99E0-320A011DB1AD

P2860

Q33978040-03C145D4-0472-4E24-A31F-E113EABA9E11

Q33978040-0903F807-5B73-47E0-9524-71718DEC3DB6

Q33978040-0B43BBC6-63FE-44CA-B859-AB58D03D7639

Q33978040-118AA3A2-9D6D-4E46-808A-EA58606D17C2

Q33978040-14F76589-43DE-4689-8A70-FF64CFB2DDB4

Q33978040-1585D278-B6BF-4820-AED5-5DF584482FD0

Q33978040-211A074F-435B-450C-8A17-A09292CBF028

Q33978040-316E4DD7-9F88-4F30-8D82-1034B30EA622

Q33978040-3983CD0A-10DF-4894-A4D2-493A62D0F5C2

Q33978040-3B684696-9D7B-4E90-BE4D-DAFB9932830C

P304

Q33978040-DE29A445-97A4-49D1-9B2B-1E41A3948423

P31

Q33978040-394D63B3-979E-4511-8510-AA7957CF77EF

P356

Q33978040-19383C38-BFC5-461C-A865-56C434E01023

P407

Q33978040-BD9C9F05-2B1D-4DAE-BDA2-E1AC010D9110

P433

Q33978040-4F173245-E32E-4D1F-A293-03359438E407

P478

Q33978040-74000175-7791-45FE-AE34-76AB264915D2

P50

Q33978040-1B7AB5C7-8D24-4C77-A19E-141F8ED43885

P577

Q33978040-3142DBD9-9311-4113-A5EA-2498721E17EE

P5875

Q33978040-979A57C6-253F-4D67-BEB8-3C8EBC43F9CC

P698

Q33978040-1F7F3A8F-8C62-4A1A-B207-66AE4062AAA8

P932

Q33978040-9A13D9B6-8852-42C6-9CFD-7D25A3571C25

P356

0008-5472.CAN-13-1506

P1433

Cancer Research

P1476

VISTA Regulates the Development of Protective Antitumor Immunity.

@en

P2093

Isabelle Le Mercier

http://www.w3.org/2001/XMLSchema#string

Janet L Lines

http://www.w3.org/2001/XMLSchema#string

Jiannan Li

http://www.w3.org/2001/XMLSchema#string

Li Wang

http://www.w3.org/2001/XMLSchema#string

Maria Day

http://www.w3.org/2001/XMLSchema#string

Randolph J Noelle

http://www.w3.org/2001/XMLSchema#string

Wenna Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Tumor-specific Th17-polarized cells eradicate large established melanoma

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Nivolumab plus ipilimumab in advanced melanoma.

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Cancer-related inflammation

Myeloid-derived suppressor cells as regulators of the immune system

P304

1933-1944

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-13-1506

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Petra A Sergent

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261293896

http://www.w3.org/2001/XMLSchema#string

P698

24691994

http://www.w3.org/2001/XMLSchema#string

P932

4116689

http://www.w3.org/2001/XMLSchema#string